Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

OSI Pharmaceuticals updates anticancer programs

Nov. 13, 1998

Favorable phase III trial results presented for Evacet at ESMO; company prepares NDA

Nov. 12, 1998

Small-molecule FGFR-1 tyrosine kinase inhibitor with nanomolar potency and good selectivity

Nov. 12, 1998

Protein tyrosine kinase inhibitors for cancer, polycystic kidney disease

Nov. 12, 1998

New anticancer drug candidate revealed by Sugen; product enters phase I testing in U.K.

Nov. 11, 1998

Promising interim results announced for SU-5416 phase I trial

Nov. 10, 1998

Two major clinical studies demonstrate chemo- and radioprotective activity of amifostine

Nov. 10, 1998

Ribozyme initiates phase I clinical trials of Angiozyme

Nov. 9, 1998

GBC-590 effective in murine model of treatment-resistant pancreatic cancer

Nov. 9, 1998

Progen commences phase I trials of PI-88 in the U.K.

Nov. 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...